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Abstract Sarcopenia, broadly defined as the age-
related decline in skeletal muscle mass, quality, and
function, is associated with chronic low-grade inflam-
mation and an increased likelihood of adverse health
outcomes. The regulation of skeletal muscle mass with
ageing is complex and necessitates a delicate balance
between muscle protein synthesis and degradation. The
secretion and transfer of cytokines, long non-coding
RNAs (lncRNAs) and microRNAs (miRNAs), both
discretely and within extracellular vesicles, have
emerged as important communication channels be-
tween tissues. Some of these factors have been im-
plicated in regulating skeletal muscle mass, function,
and pathologies and may be perturbed by excessive
adiposity. Indeed, adipose tissue participates in a
broad spectrum of inter-organ communication and
obesity promotes the accumulation of macrophages,
cellular senescence, and the production and secretion
of pro-inflammatory factors. Pertinently, age-related
sarcopenia has been reported to be more prevalent in
obesity; however, such effects are confounded by
comorbidities and physical activity level. In this re-
view, we provide evidence that adiposity may
exacerbate age-related sarcopenia and outline some
emerging concepts of adipose-skeletal muscle com-
munication including the secretion and processing of
novel myokines and adipokines and the role of ex-
tracellular vesicles in mediating inter-tissue cross
talk via lncRNAs and miRNAs in the context of
sarcopenia, ageing, and obesity. Further research
using advances in proteomics, transcriptomics, and
techniques to investigate extracellular vesicles, with
an emphasis on translational, longitudinal human
studies, is required to better understand the physio-
logical significance of these factors, the impact of
obesity upon them, and their potential as therapeutic
targets in combating muscle wasting.
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Introduction
Beyond middle-age, skeletal muscle mass, and strength
decline by 1–2% and 1–5% per year, respectively [1–3].
Skeletal muscle tissue is the human body’s principle
protein bank, and given the absence of a protein pool
for storage, it is critical for maintaining protein status via
the delicate regulation of its turnover [4, 5]. Indeed, the
maintenance of skeletal muscle mass, quality, and func-
tion with ageing is multifactorial and necessitates a
balance of regulatory processes in response to inherent
biological ageing, physical in/activity, injury, or illness
[6]. These processes include the generation of muscle
via adult myogenesis (comprising the activation of mus-
cle satellite cells, the proliferation of myoblasts; the
withdrawal of myoblasts from the cell cycle, their sub-
sequent differentiation and fusion into multinucleated
myofibres) [7, 8], the repair and remodelling of muscle
tissue [9] and its inter- and intracellular content [10], the
interaction between skeletal muscle and the nervous
system via motor neurones [11], and the interplay be-
tween synthesis and breakdown of muscle protein [12,
13].
Sarcopenia, broadly defined as the age-related de-
cline in skeletal muscle mass, quality, and function, is
the product of a negative balance of these muscle regu-
latory processes and is associated with an increased
likelihood of adverse health outcomes [14]. Sarcopenia
has been reported to be more prevalent in adults with
obesity [15]. Adiposity exacerbates sarcopenia, in-
creases fat infiltration in muscle, and reduces physical
function [14, 16, 17]. The state of concurrent obesity
and sarcopenia is considered by some to constitute a
discrete condition, termed sarcopenic obesity; however,
there is a lack of consensus surroundings its definition
and diagnostic criteria [18–20]. Individuals presenting
with sarcopenic obesity may have greater absolute mus-
cle mass than is typical of individuals with sarcopenia,
but the quality and function of that muscle (including
muscle strength) are reduced, which may exacerbate
muscle deterioration with ageing [21–24].
Critically, as our population becomes increasingly
aged and obese, the ramifications of obesity on the mass
and function of skeletal muscle with age warrant rigor-
ous investigation [25, 26]. In this review, we outline
some emerging conduits of adipose-skeletal muscle
communication in the context of sarcopenia and obesity
including the secretion and processing of novel
myokines and adipokines, as well as the significance
of cellular senescence on the adipose tissue secretome,
and the role of extracellular vesicles and non-coding
RNAs in mediating inter-tissue cross talk. We principal-
ly focus on sarcopenia and obesity as two distinct but
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often converging conditions. We also present evidence
investigating the phenomenon of sarcopenic obesity and
discuss the myriad ways that obesity may interact with
sarcopenia to the detriment of muscle mass, quality, and
function.
Adipose tissue as an endocrine organ
Once considered a passive energy reservoir, the discov-
ery of the adipose-secreted factors adipsin and leptin
confirmed adipose tissue as an endocrine organ
[27–29]. Following the initial observation that obese
adipose tissue has increased expression and secretion of
tumour necrosis factor-alpha (TNF-α), it has been shown
that obesity leads to the accumulation of macrophages
within adipose tissue, which promote the production and
secretion of several pro-inflammatory cytokines [30, 31].
Moreover, cellular senescence in adipose tissue, common
to both ageing and obesity, is now understood to contrib-
ute to inflammation, aberrant cytokine production, and
metabolic dysfunction [32]. Adipose tissue is now
known to participate in a broad spectrum of inter-organ
communication [33] and excessive adiposity conveys
pleiotropic effects on its endocrine and metabolic func-
tion, contributing to pathophysiological consequences
with ageing [34, 35]. Importantly, this has to be consid-
ered in the context of evidence from studies that demon-
strated a capacity for healthy adipose tissue to exert
favourable effects on skeletal muscle that further supports
the physiological importance of cross talk between the
two tissues [36].
Inter-tissue communication via multiple means
Historically, communication between cells was thought
to bemediated by cell-cell contact or by the extracellular
secretion of molecules, principally cytokines, a broad
family of small secreted proteins, which can confer
autocrine, paracrine, and endocrine effects on multiple
tissues [37]. While cytokines can be secreted discretely,
accumulating evidence has demonstrated that they may
also be transported by the secretion and transfer of
extracellular vesicles (EVs) and that certain cytokines
may also serve to regulate the packaging and trafficking
of these EVs [38]. EVs, principally divided into
exosomes and microvesicles, are respectively released
into the extracellular environment from endosomal and
plasma membrane origins and are reviewed elsewhere
[39, 40]. Alongside cytokines, EVs contain a broad
array of cargo including proteins, lipids, organelle com-
ponents, and myriad non-coding RNAs, which have
emerged as an important communication channel be-
tween tissues [41]. Pertinently, the discrete and EV-
mediated secretion and processing of novel cytokines,
long non-coding RNAs (lncRNAs), and microRNAs
(miRNAs), from adipose and skeletal muscle tissue,
have been implicated in the regulation of skeletal muscle
mass, function, and pathologies, in the context of obe-
sity and ageing [42, 43] (Table 1).
Senescence-associated secretory phenotype
Cellular senescence is an evolutionarily conserved age-
ing mechanism characterised by upregulation of cyclin-
dependent kinase inhibitor genes, which in turn activate
retinoblastoma protein to block cell cycle progression
[92–94]. Senescence arises in response to cellular stress
and damage, including metabolic insults [95, 96]. While
this serves to restrain harmful growth and replication of
damaged cells, senescent cells also secrete an array of
cytokines, chemokines, growth factors, and matrix-
remodelling proteases, collectively termed the
senescence-associated secretory phenotype (SASP)
[97, 98]. Senescent cells are resistant to apoptosis and
are ordinarily cleared by the immune system but accu-
mulate with ageing [99, 100]. Conditioned media from
primary human pre-adipocytes with induced senescence
via serial passage or irradiation demonstrate a SASP that
is rich in pro-inflammatory interleukins, interferon gam-
ma (IFN-γ), and TNF-α, which could negatively impact
upon muscle regulation [101].
Accumulation of senescent cells within metabolic
tissues, such as adipose and skeletal muscle, is deleteri-
ous to metabolic homeostasis [95, 102–104], and obe-
sity may promote the senescent state [105]. Indeed, the
adipose tissue of individuals with obesity displays ele-
vated oxidative stress and accelerated telomere shorten-
ing [106, 107], which are purported to induce and pro-
mote senescence [108, 109]. It has been proposed that
obesity and ageing drive excessive turnover of adipose
progenitors which may contribute to the onset of their
senescence and subsequent SASP, conveying both local































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The potential benefit of modulating cellular se-
nescence has been recently investigated. Adminis-
tration of Dasatinib and Quercetin, which target
and eliminate senescent cells, to omental adipose
tissue explants from middle-aged adults with obe-
sity reduced the abundance of senescent cells and
decreased pro-inflammatory cytokine secretion
[111]. No study to date has directly investigated
whether adipose tissue senescence is implicated in
sarcopenia and whether this is amplified by obesity.
However, the accumulation of intramuscular adipose
tissue that is common to both ageing and obesity [112,
113], the pro-inflammatory adipose SASP observed in
those states, and the ability of senescent cells to confer
senescence to their microenvironment suggest that this
relationship is plausible [17, 114]. To this effect, long-
term studies into the implications of adipose senescence
and the viability of anti-senescent therapeutics in
sarcopenia are needed. It must be considered, however,
that the human lifespan is vastly different to that of
rodents, fromwhommost existing data is derived. Thus,
any deleterious effects of cytotoxic therapies to remove
senescent cells may be amplified over the course of
human ageing [92].
Cytokines as mediators of adipose-muscle cross talk
The decline of skeletal muscle mass in various inflam-
matory states is associated with elevated production of
classical pro-inflammatory cytokines, including TNF-α,
interleukin (IL)-1 beta (IL-1β), IL-6, and IFN-γ [115].
The low-grade inflammation associated with ageing,
termed “inflammaging,” is influenced not only by over-
production of pro-inflammatory mediators but also by
perturbation of anti-inflammatory factors, such as IL-10
[116–119]. While far from being fully understood, the
roles of such classical cytokines in ageing muscle have
been reviewed elsewhere [115, 120–122]. Accordingly,
here we focus on cytokines which are implicated in
adipose-muscle cross talk with emerging significance
in the regulation of skeletal muscle mass, namely
resistin, IL-15, adiponectin, leptin, lipocalin-2, and
myostatin (Fig. 1; Table 1).
Resistin
Resistin was first identified in rodents as an adipocyte-
secreted factor that is upregulated in obesity and impairs
glucose tolerance, insulin action, and fatty acid handling
in skeletal muscle [123–126]. While the significance
and even existence of resistin in human adipocytes
has been contentious [127], by analysing conditioned
medium from subcutaneous adipose tissue (SAT)
from lean and obese humans, rather than isolated
adipocytes, we recently found it to be secreted from
SAT and increased with obesity [47]. This highlights
the importance of stromal and infiltrating immune
cells to the inflammatory in vivo phenotype of adi-
pose tissue [128].
Notably, incubation of primary human myotubes
from lean individuals with SAT-conditioned media
obtained from obese subjects produced thinner, less
multinucleated myotubes than those exposed to lean
SAT secretome, which is concordant with findings
using co-culture systems of human myotubes and
adipocytes isolated from visceral adipose tissue
(VAT) [47, 129]. Pertinently, the deleterious effects
of the obese SAT secretome were more pronounced in
myotubes derived from older than younger individ-
uals, suggesting ageing impairs the ability of muscle
to withstand inflammatory challenges. Since resistin
was prolifically secreted from obese SAT, further
investigation revealed that a physiologically relevant
concentration of resistin (5 ng mL−1) impaired myo-
blast differentiation through activation of the classical
nuclear factor-kappa beta (NF-κβ) pathway, similarly
producing thinner myotubes with reduced nuclear
fusion [47]. This adverse effect of resistin was con-
firmed in experiments showing that its depletion from
obese SAT secretome restored myogenesis [47]. Con-
sistent with these findings, overexpression of resistin
impairs C2C12 myoblast differentiation, resulting in
thinner myotubes with reduced expression of desmin
and myoglobin [44].
In vivo research on the effects of resistin on regu-
lating skeletal muscle mass and function is scant.
However, human plasma resistin concentrations cor-
relate with inflammatory markers [130], have been
reported to correlate with age [45], and in the elderly
are inversely associated with quadriceps torque [46]
and computed tomography determinants of abdomi-
nal muscle density (a marker of muscle quality and
composition) [131]. Collectively, the limited litera-
ture suggests an emerging role for resistin in sup-
pressing myogenic differentiation, particularly in




IL-15, a four-helix bundle family cytokine, is produced
by a variety of tissues, including skeletal muscle and
adipose. Its mRNA expression is upregulated during the
differentiation of C2C12 myoblasts and it is also
expressed in pre- and post-differentiated 3T3-L1 adipo-
cytes, albeit at a comparatively much lower level [132].
IL-15 mRNA expression in mouse epididymal adipose
tissue and adipose tissue macrophages is increased in
response to a high-fat diet (HFD) [133]. IL-15 was
originally observed to have pro-myogenic effects on
murine C2 skeletal muscle cells by promoting the accu-
mulation of contractile proteins [134, 135]. Such effects
may be mediated by supressing muscle proteolytic path-
ways. Indeed, ex vivo incubation of rat muscle tissue
with recombinant IL-15 decreased the rate of proteoly-
sis, without a change in total protein synthesis or tissue
amino acid uptake [136]. Similarly, in vivo studies
showed that septic mice pre-treated with IL-15 had
lower expression of the proteolytic E3 ubiquitin ligases
muscle atrophy F-box gene/atrogin-1 (MAFbx) and
Fig. 1 Cytokines secreted from skeletal muscle and adipose tis-
sues with emerging significance in muscle-adipose cross talk and
the regulation of skeletal muscle mass. The expression, secretion,
extracellular-vesicle-mediated transport, and function of these cy-
tokines may be perturbed by ageing and obesity, impairing normal
muscle regulatory pathways. Processes regulating skeletal muscle
mass have been condensed into four fundamental levels: activation
of the muscle satellite cell pool; proliferation of myoblasts; differ-
entiation of myoblasts into myotubes; and the ubiquitin (Ub)
catabolic processes involved in the breakdown of muscle protein.
Regardless of colour, arrows and block (inhibitory) lines indicate
stimulatory and inhibitory effects, respectively, of a particular
cytokine on these regulatory levels. Red lines (whether arrows or
block lines) indicate pro-myogenic effects, which may act to
preserve muscle mass, while black lines (whether arrows or block
lines) indicate anti-myogenic effects which may confer adverse
effects on muscle mass. The effects of ageing without obesity
(silhouetted figure on the left) and ageing combined with obesity
(silhouetted figure on the right) to increase or decrease the secre-
tion and/or circulating abundance of these cytokines is indicated
by thick black upward or downward-pointing arrows, respectively.
Two upward arrows indicate a greater effect of obesity than the
lean state on the relevant cytokine with ageing. A question mark
indicates an unknown effect. An inhibitory line extending from a
running person indicates that the proposed effect of ageing is offset
when physical activity level is maintained with ageing. An inhib-
itory line extending to a cytokine receptor indicates that an in-
creased abundance of that cytokine is associated with a reduction
in expression of its receptor in skeletal muscle. Created with
BioRender.com
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muscle ring finger-1 (MuRF-1), and IL-15 treatment of
cachexic rats decelerated protein degradation and sup-
pressed expression of ubiquitin proteolysis pathway
components [48, 137].
We also reported that exposing primary myogenic
cultures from young and elderly adults to recombinant
IL-15 during differentiation resulted in thicker
myotubes that were protected against differentiation
impairment by TNF-α [49]. However, subcutaneous
administration of recombinant IL-15 in rats for 7 days
did not impact upon net muscle mass or protein content,
although it increased turnover by accelerating both pro-
tein synthesis and breakdown rates and decreased white
adipose tissue (WAT) mass by 33% [138]. Taken to-
gether, the literature supports a muscle-sparing effect of
IL-15, particularly in conditions of dysregulated protein
turnover such as cancer cachexia and possibly
sarcopenia, through the suppression of muscle protein
catabolism. However, IL-15 appears to have limited
effects on muscle anabolism, particularly in healthy
states.
We recently demonstrated in healthy older adults that
IL-15 muscle mRNA expression and plasma concentra-
tion are elevated 2-fold and 1.5-fold, respectively, rela-
tive to younger adults [49]. However, IL-15 receptor
signalling subunit IL2RB expression was 80% lower in
older muscle, suggesting that the intracellular pro-
myogenic effects of IL-15 may be blunted in the elderly.
In a separate study, plasma IL-15 concentrations were
found to be lower in sarcopenic compared to non-
sarcopenic older adults and inversely correlated with
sarcopenic state and body mass index (BMI) [50]. With
regard to adiposity and IL-15 expression, obese individ-
uals present with lower serum IL-15 than normal-weight
individuals and IL-15 knockout inmice results in weight
gain [139]. Interestingly, the aforementioned study that
examined the effect of recombinant IL-15 administra-
tion in rats reported a decline in WAT mass [138].
It is important to note that levels of tissue IL-15
mRNA are not necessarily concordant with IL-15 pro-
tein expression and secretion, on account of inefficient
translation due to multiple AUG initiation sites in the 5′-
untranslated region [140]. Furthermore, alternative
splicing produces two mature isoforms, only one of
which follows the secretory pathway [141]. The seem-
ingly contradictory observations of increased IL-15
mRNA expression in ageing and reduced circulating
IL-15 abundance in sarcopenia may therefore demon-
strate a transcriptional attempt to offset some impaired
translational or secretory capacity that may occur with
inflammaging, in an attempt to mitigate the catabolic
effects of declining circulating IL-15.
Collectively, the literature suggest that IL-15 expres-
sion and function is tightly regulated at multiple levels
and plays a significant role in the preservation of skeletal
muscle mass. Its significance appears greatest within an
atrophic, inflammatory state, such as that commonly
observed with ageing, where it may have therapeutic
potential through amelioration of processes involved in
protein degradation.
Adiponectin
Adiponectin is the most abundant peptide secreted by
adipocytes and plays a key role in energy homeostasis
[142–144]. Adiponectin functions through the binding
of the adaptor protein APPL1 (phosphotyrosine
interacting with PH domain and leucine zipper 1), to
the AdipoR1 and AdipoR2 receptors, and promotes
interaction between the insulin receptor (IR) and its
substrates IRS1/2, consequently priming the
phosphatidylinositol-3-kinase (PI3K) pathway
[145–147]. In skeletal muscle, adiponectin enhances
p38 mitogen-activated kinase (MAPK)/peroxisome
proliferator-activated receptor gamma coactivator 1-
alpha (PGC-1α) signalling and mitochondrial biogene-
sis [148, 149], and stimulates activation of adenosine
monophosphate-activated protein kinase (AMPK) and
acetyl-CoA carboxylase [150–152].
Unlike many adipocyte-secreted factors, adiponectin
expression and secretion are greatest from healthy adi-
pocytes of lean individuals and are inhibited by pro-
inflammatory agents [124, 153, 154]. Accordingly,
adiponectin levels decrease with obesity and type 2
diabetes mellitus (T2D) and correlate positively with
insulin sensitivity and negatively with visceral adiposity
[155–157]. Pertinently, circulating adiponectin is lower
in sarcopenic than non-sarcopenic older adults [51] but
does not differ between physical activity-matched non-
sarcopenic older and younger adults, suggesting that it is
not ageing per se driving reduced adiponectin concen-
tration, but rather an age-associated decline in habitual
physical activity level [52]. Conversely, circulating
adiponectin was found to be higher in cardiovascular
disease (CVD) patients with sarcopenia than without.
However, the sarcopenic CVD group were predomi-
nantly female (66% female compared to a 28% female
non-sarcopenic group) who typically present with
GeroScience
higher adiponectin concentrations [158–160]. Neverthe-
less, some studies have suggested that elevated
adiponectin may predict reduced muscle strength and
function in older adults [161, 162]. Therefore, the higher
levels of adiponectin in sarcopenic individuals reported
in some studies could reflect a compensatory adaptation.
Such a compensatory induction could be an attempt to
preserve the p38 MAPK translational initiation path-
way, the activation of which is dysregulated in human
ageing [163], thus protecting against age-related impair-
ment of protein synthetic pathways.
Globular adiponectin activates muscle satellite cells,
promotes their motility, induces muscle gene expression
including myosin heavy chain (MHC), myogenin, and
p21, and drives myoblasts to exit the cell cycle, promot-
ing differentiation [53–55]. Adiponectin overexpression
increased regenerating myotubes in a mouse model of
ageing and heart failure [164]. Adiponectin was found
to accumulate on the myofibre plasma membrane and
intracellularly co-localised with endosomes positive for
the multivesicular/exosome marker cluster of
differentiation-63 in regenerating, but not intact, fibres.
However, in T-cadherin-null mice myotube regenera-
tion was not increased by adiponectin overexpression,
suggesting an essential role of T-cadherin in mediating
these effects [164]. The authors demonstrated that both
globular adiponectin and a small molecule mimetic
(GTDF) induced differentiation and supressed MURF1
and MAFbx in various atrophy models, preventing the
loss of myotube area [165]. Crossing degenerative
muscle-diseased mice with mice overexpressing
adiponectin improved expression of the myogenic dif-
ferentiation markers myogenic regulatory factor-4 and
myogenin, while reducing muscle inflammation and
oxidative stress, resulting in higher muscle force and
endurance [166]. Although this appears to contradict
findings from human studies [161, 162], it supports
the aforementioned possibility of a protective role of
adiponectin on skeletal muscle mass in dysregulated
states.
Confoundedly, stimulation of C2C12 cells with an
adiponectin receptor agonist (AdipoRon) reduced cellu-
lar protein content, myotube diameter, and myotube
multinucleation in a dose-dependent fashion (5–
20 μM). However, the relevance of the dose utilised to
physiologically elevate adiponectin concentrations is
not well understood [167]. In mice, the extensor
digitorum longus (fast twitch), but not soleus (slow
twitch) muscle, exhibited increased adiponectin
expression with ageing, though adiponectin receptor
expression was unchanged [167]. The authors proposed
that excessively high circulating adiponectin may in-
duce skeletal muscle atrophy within fast-type muscle.
However, neither serum AdipoRon nor adiponectin
were measured in this study, limiting extrapolation and
comparison to humans. Given that adiponectin activates
AMPK, and AMPK activity has an inhibitive effect on
mammalian target of rapamycin (mTOR), which plays a
central role in protein synthesis, it is plausible that
highly elevated adiponectin could exert negative effects
on muscle mass regulation by excessive activation of
AMPK [168–171]. Thus, it has been speculated that
there is a healthy circulating adiponectin range required
to maintain normal adiponectin signalling, though this
purported range has not yet been clearly defined [171].
Leptin
Leptin is a cytokine-like hormone that is abundantly
secreted by adipocytes but is also expressed in skeletal
muscle [172]. Leptin conveys satiety-promoting effects
and plays a significant role in the regulation of energy
balance and body mass, as well as lipolysis and insulin
sensitivity, which has been reviewed elsewhere
[173–176]. Circulating leptin concentration increases
with obesity, correlates with BMI and adipose tissue
mass [81, 177–180], and is reduced with weight loss
[181–184]. Pertinent to the regulation of skeletal muscle
mass, leptin administration increases hindlimb muscle
mass and fibre size in aged mice [56], and prevents
muscle atrophy in leptin-deficient mice [57]. Mechanis-
tically, the binding of leptin to the long form of its
receptor, activates Janus kinase 2 (JAK2), subsequently
promoting PI3K activity and phosphorylation of protein
kinase B (Akt) and p38 MAPK [58, 185–188]. Leptin
promotes C2C12 myoblast proliferation but suppresses
expression of myogenin and myoblast determination
protein (MyoD), which is mediated by JAK-STAT (sig-
nal transducer and activator of transcription) andMAPK
pathways [59]. Despite the propensity for leptin to pro-
mote pathways involved in muscle regulation, its
obesity-mediated upregulation is associated with resis-
tance to its action [176, 189–191]. Central leptin recep-
tor expression may be reduced as a direct result of
increased leptin abundance [192–194]. Concordantly,
skeletal muscle protein expression of the long leptin
receptor is lower in adults with obesity, suggesting one
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mechanism by which peripheral leptin resistance may
occur [60].
While circulating leptin is elevated in animal models
of ageing in the absence of obesity [195], it has been
reported to decline in elderly adults with severe frailty,
but not in community-dwellers [61]. This decline may
reflect not only the low abundance of adipose tissue
often seen in frail older adults but also the diminishing
mass of skeletal muscle, which is also a significant
source of leptin [196–198]. Conversely, in community
dwelling older adults, appendicular skeletal muscle
mass and thigh muscle cross-sectional area have been
negatively associated with plasma leptin concentration,
even after adjustments for bodyweight or body fat per-
centage [62, 63]. In these studies, circulating leptin
abundance was greater in those presenting with either
sarcopenia or obesity, and greater still in individuals
presenting with sarcopenic obesity. Interestingly, phys-
ical inactivity in the form of bed rest, which is often
characteristic of frail older adults, also increases leptin
levels independent of changes in fat mass [199]. It could
be argued that physical inactivity increases leptin secre-
tion in an attempt to preserve muscle mass, which may
be ineffective in an aged-obese environment due to
existing leptin resistance. Collectively, the literature
suggests that both sarcopenia and obesity may promote
a hyperleptinaemic environment that drives peripheral
leptin resistance via the downregulation of its receptor.
Thus, obesity may amplify resistance to the muscle-
preserving effects of leptin in ageing and contribute to
the sarcopenic-obese state.
Lipocalin 2
Lipocalin 2 (Lcn2) is a secretory glycoprotein first iden-
tified in human neutrophils and later noted for its abun-
dant expression in adipocytes [200–202]. Both Lcn2
and its cell surface receptor (24p3R) have also been
found to be expressed in skeletal muscle [64, 203].
Lipocalins bind and transport small hydrophobic mole-
cules such as fatty acids, steroids, and retinol [200].
Lcn2 is induced by factors that drive insulin resistance
and inflammatory stimuli, with transactivation by the
pro-inflammatory transcription factor NF-κβ [65, 204].
Circulating Lcn2 is elevated with obesity and correlates
with adiposity, adipose distribution, and inflammatory
markers, though the significance of this relationship is
contestable and not necessarily causal, with Liu et al.
observing circulating Lcn2 to neither correlate with nor
predict the incidence of insulin resistance or cardiovas-
cular risk factors [66, 202, 205, 206].
Adipose Lcn2 mRNA and protein expression is
greater in humans and rodents that are obese, compared
to those of normal-weight [67, 200, 202]. Catalán et al.
found plasma Lcn2 concentration was not affected by
obesity; however, circulating Lcn2/matrix metallopro-
teinase (MMP) complex abundance and VAT MMP-2
and MMP-9 activity were elevated [67]. Given the role
of the MMP system in adipocyte differentiation and
SAT and VAT remodelling, this may implicate Lcn2
in the development of obesity [207–209]. On the other
hand, it has recently been argued that rather than being
causal of metabolic dysfunction, elevated Lcn2 may
instead provide a protective mechanism to mitigate
obesity-induced dysregulation and preserve pancreatic
β-cell function [210]. Indeed, global Lcn2 knockout in
mice was recently shown to accelerate age-dependent
weight gain and visceral fat deposition in female mice,
although curiously this was not the case in male mice
[211].
Rebalka et al. investigated the role of Lcn2 in
regenerating skeletal muscle and the effects of Lcn2
deletion [64]. While Lcn2 protein was lowly expressed
in uninjured mouse skeletal muscle, its expression in
Pax7+ muscle satellite cells was increased in response to
cardiotoxin injury. In contrast, global Lcn2 knockout
mice had reduced satellite cell activation and diminished
muscle regeneration, with decreased embryonic MHC
expression and smaller myofibre areas. However, the
effects on adipose tissue were not studied. Finally, con-
sistent with the role of Lcn2 in MMP regulation, Lcn2
knockout mice displayed greater fibrosis and lower
MMP-9 activity during muscle regeneration.
The relationship between adipose-derived Lcn2 and
skeletal muscle regulation is not yet fully understood,
with reports of global Lnc2 knockout in C57BL/6 mice
conferring both protection from, and potentiation of,
diet- and ageing-induced metabolic dysregulation
[212–214]. Initial investigations have shown that anti-
diabetic drugs can counteract obesity-upregulated Lcn2
expression and circulating abundance in rats, T2Dmice,
and humans with T2D [200, 206]. However, reports of
acute, but not chronic, exercise elevating circulating
Lcn2 abundance in obese adults suggests that the rela-
tionship between Lcn2 and metabolic health is complex
[215, 216]. Furthermore, it is not yet clear how modu-
lation of circulating Lcn2 might impact skeletal muscle
regulation. Therefore, studies employing muscle and
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adipose tissue-specific deletion as well as overexpres-
sion or administration of recombinant Lcn2 within ro-
dent models of ageing and muscle wasting are
warranted.
Myostatin
Myostatin is a transforming growth factor-beta (TGF-β)
superfamily member that negatively regulates muscle
mass and whose disruption produces hyper-
muscularity [68]. Myostatin signals through activin-
responsive type II receptors (ACTRIIA and ACTRIIB)
and the type I receptors, activin-like kinases, triggering
activation of small mothers against decapentaplegic
(SMAD)2 and SMAD3 transcription factors, resulting
in the inhibition of hypertrophic and activation of atro-
phic pathways [69, 217–221]. Recombinant myostatin
impairs myogenesis through suppression of satellite cell
activation and myoblast proliferation and differentia-
tion, while genetic inactivation impairs myotube forma-
tion in vitro [70–72, 222, 223]. Myostatin expression
and abundance is reportedly, though not universally,
elevated with obesity, advancing age and muscle
wasting, and decreased by weight loss [73, 224–229].
Whether the deleterious association of obesity and
myostatin expression reflects an effect of excessive
adipose tissue per se, or the product of an obesogenic
muscle environment, remains unclear. Similarly, exer-
cise is a potent suppressor of myostatin expression
[230–232], and thus physical activity status adds a fur-
ther confounding variable that is not always controlled
for. Nevertheless, primary myotubes generated from
morbidly obese individuals exhibit ~ 2-fold greater
myostatin protein content and ~ 3-fold greater secretion
thanmyotubes from lean donors, and mRNA expression
is similarly elevated in morbidly obese muscle [73,
233].
Myostatin is also expressed in adipose tissue; how-
ever, data from ob/ob mice suggest mRNA expression is
50–100-fold lower than in skeletal muscle [234]. Impor-
tantly, myostatin expression was assessed in the tibialis
anterior, a muscle comprised almost exclusively of fast
fibres [235]. Since MHC IIb (a fast twitch myosin)
expression correlates withmyostatinmRNA expression,
this may in part explain the magnitude of difference
reported between muscle and adipose myostatin expres-
sion [236]. Nevertheless, both myostatin and ActRIIB
mRNA expression were 50–100-fold higher in ob/ob
than wild-type adipose tissue. Conversely, despite
elevated serum abundance, myostatin expression in
SAT and VAT was not different between age-matched
severely obese, lean, and overweight humans [237]. It is
plausible that the contradictory findings between obese
human and murine adipose tissue myostatin expression
reflect fundamental differences between human and
murine adipose expression profiles and brown adipocyte
abundance [238, 239].
Adipose tissue-specific deletion of myostatin in mice
fed a HFD did not affect muscle weight nor body
composition; however, whole-body knockout partially
supressed HFD-induced fat accumulation [77, 240].
Conversely, muscle-specific inhibition of myostatin sig-
nalling increased lean mass and decreased fat mass in
both chow and high-fat diets [77]. These studies suggest
that secretion and signalling of myostatin in skeletal
muscle influence the regulation of muscle and adipose
mass. However, myostatin secretion and its signalling in
adipose tissue have little impact on either adipose or
muscle regulation, reflecting its vastly lower expression
in adipose tissue.
Ageing appears to upregulate myostatin expression
independent of adiposity, which if translated to in-
creased myostatin protein secretion could contribute to
sarcopenia by promoting atrophic and inhibiting hyper-
trophic pathways via canonical TGF-β signalling. Mus-
cle myostatin mRNA and protein expression was 2.0-
fold and 1.4-fold higher, respectively, in older than
younger males [224] and myostatin mRNA expression
was 56% greater in elderly than young women [74].
Older males matched with younger males for total- and
lean-body mass and body fat percentage tended to have
higher basal muscle myostatin mRNA expression and
significantly greater muscle myostatin protein content
[75]. Whether elevated myostatin expression with ad-
vancing age is a function of ageing per se or a product of
age-associated physical inactivity, systemic inflamma-
tion, or nutritional status remains poorly investigated.
Interestingly, muscle myostatin mRNA was found to be
lower in both ambulatory and non-ambulatory elderly
women than young women [76]. Myostatin protein
content was greatest in the old ambulatory group, with
no difference in plasma concentrations between groups.
Similarly, higher concentrations of serum myostatin
have been reported in non-frail compared to frail nursing
home residents, and its abundance was increased in
male residents, of both frail and non-frail status, follow-
ing chronic exercise [241]. Evidently, further research is
necessary to characterise and delineate between the
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effects of advancing age, adiposity, and physical inac-
tivity on human myostatin expression and function
in vivo.
Long non-coding RNAs: emerging roles in skeletal
muscle regulation
Only ~ 1% of the human genome is translated into
proteins; however, much is transcribed into non-
protein-coding RNAs [242, 243]. Of these, lncRNAs,
with transcripts of > 200 nucleotides, are the largest
group and have been implicated in the regulation of
RNA transcription, splicing, and trafficking, miRNA
regulation, and RNA stability [84, 244–248]. lncRNAs
have been implicated in obesity and in obesity-
associated disorders including muscle wasting [249,
250]. Sequencing of SAT from females with and with-
out obesity identified 86 lncRNAs that were differen-
tially expressed [251]. Skeletal muscle from individuals
with inclusion body and anti-Jo-1-associated myositis, a
collection of diseases characterised by chronic muscle
inflammation and weakening, revealed a similar number
of differentially expressed lncRNAs, relative to healthy
controls [78]. Of these, 16 lncRNAs were differentially
expressed in both myositis groups, including H19,
metastasis-associated lung adenocarcinoma transcript 1
(MALAT1), plasmacytoma variant translocation 1
(PVT1), and long non-coding myoblast determination
protein (lncMyoD), which have been previously
characterised and implicated in skeletal muscle regula-
tion [84, 252, 253] (Table 1).
H19
H19 is upregulated during myoblast differentiation and
its inhibition impairs skeletal muscle differentiation
[254]. Pertinently, two miRNAs encoded by H19 ex-
on1, miR-675-3p and miR-675-5p, which are induced
during differentiation, can rescue the effects of H19
depletion through suppression of the TGF-β/bone mor-
phogenetic protein pathway. H19 expression in SAT
and VAT negatively correlates with BMI; however,
whether an obesity-associated decline in adipose H19
affects the regulation of skeletal muscle mass remains to
be investigated [255]. Given the aforementioned differ-
ential skeletal muscle expression of H19 in myositis
patients, its potential involvement in age-related muscle
wasting also warrants investigation.
MALAT1
MALAT1 expression increases during differentiation of
primary human myoblasts and its knockdown is associ-
ated with impaired proliferation and differentiation [79,
256]. Treatment of mice with recombinant myostatin
drastically reduced MALAT1 expression, which given
the positive impact of myostatin deficiency on muscle
function with ageing suggests MALAT1 may be an
important downstream target of myostatin and regulator
of myogenesis with ageing that deserves examination
[256–258]. MALAT1 can competetively bind miR-133,
de-repressing the transcription factor serum response
factor (SRF) in myoblasts, facilitating upregulation of
muscle-specific gene expression [79]. Conversely, it has
been reported that MALAT1 is downregulated during
early myogenesis and regulates differentiation through
modulation of MyoD [80]. The impact of adiposity on
MALAT1 expression in skeletal muscle and on
myogenesis has not yet been explored.
PVT1
PVT1 is activated during muscle atrophy, affecting
myofibre size, apoptosis, and mitochondrial function
[252]. Downexpression of PVT1 in muscle induces
resistance to atrophic processes in response to a dener-
vation model of muscle wasting, by modulating apopto-
sis and autophagy. PVT1 is implicated in a variety of
disease states characterised by inflammation, including
obesity where its expression in murine adipose tissue is
increased and promotes adipogenesis [82] and in osteo-
arthritis, where its suppression may ameliorate disease
progression through the repression of catabolism and
inflammation [83, 259]. However, PVT1 in ageing has
not yet received much attention and its role in the cross
talk between adipose tissue and skeletal muscle remains
unknown.
lncMyoD
Encoded next to the MyoD gene, lncMyoD is activated
by MyoD during myoblast differentiation and binds to
insulin-like growth factor (IGF) mRNA-binding protein
2 (IMP2), blocking IMP-mediated shuttling of
proliferation-promoting RNAs, inhibiting their transla-
tion and thus proliferation [84, 85]. The MyoD-
lncMyoD-IMP2 pathway demonstrates a mechanism
involved in the proliferation-inhibitive effects of MyoD,
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promoting a permissive state for differentiation. In
mice, skeletal muscle lncMyoD expression is upreg-
ulated during models of disuse atrophy including
denervation, casting, and tail suspension, but not in
models of systemic muscle wasting including dexa-
methasone administration, cancer cachexia, and
fasting [260]. Given the prevalence of physical inac-
tivity and immobilisation amongst the elderly, such
findings warrant investigations into the role and ther-
apeutic potential of lncMyoD in human muscle
ageing.
MicroRNAs: novel candidate factors
in adipose-muscle cross talk
The non-coding miRNAs are well established as key
mediators of gene expression through post-
transcriptional downregulation, translational repression,
and deadenylation-dependent decay and are abundant
within EVs [261–268]. Most miRNAs are first tran-
scribed into primary miRNAs (pri-miRNAs), processed
by the RNase III enzymes Drosha, forming precursor
miRNAs (pre-miRNAs), and Dicer, yielding mature
miRNAs [269–271]. Recent reviews and systematic
analyses of microarrays and next-generation sequencing
have highlighted a plethora of miRNAs that are differ-
entially expressed in skeletal muscle and/or plasma with
ageing and muscle wasting, though the functional roles
of many of these novel miRNAs remain to be elucidated
[89, 272–275]. Similarly, within metabolic tissues and
the circulation, numerous miRNAs have been implicat-
ed in the pathological development of obesity and may
serve important functions in metabolic organ cross talk
[276–281].
Whether obesity exacerbates sarcopenia through
miRNA-mediated adipose-muscle cross talk is unclear.
However, the capacity for adipose tissue to mediate
metabolic cross talk with skeletal muscle via miRNAs
is evident. Indeed, Wang et al. showed that miR-130b is
secreted from adipocytes during adipogenesis; its WAT
mRNA expression is increased with obesity; its circu-
lating abundance is elevated in human and murine obe-
sity, correlates with BMI, and predicts the metabolic
syndrome; and it is able to target muscle cells,
supressing expression of its target gene, PGC-1α [282].
While direct investigations of possible miRNA-
mediated cross talk in the context of age-related muscle
wasting and obesity remain to be undertaken, separate
investigations have uncovered differentially expressed
miRNAs common to both ageing and obesity, including
miR-31, miR-223, and miR-33a [283, 284]. Such
miRNAs may present candidate mediators of the ad-
verse effects of obesity on muscle mass regulation
(Table 1).
miR-31, miR-223, and miR-33a
Administration of leptin to aged mice increased muscle
mass and expression of miR-31 and miR-223, which are
known to be elevated during muscle regeneration and
repair [56]. Given the aforementioned (“Leptin” section)
potential role of leptin in the regulation of skeletal
muscle mass, this suggests a channel by which miRNAs
may be involved in mediating a beneficial effect of
leptin in ageing muscle [56, 284].
miR-33a is expressed in both human skeletal muscle
and adipose tissue [285] and encoded within sterol
regulatory element-binding protein 2, a transcription
factor involved in lipid biosynthesis and trafficking
[286]. The circulating level of miR-33a is lower in older
than younger adults in both the presence and absence of
insulin resistance [283]. It has been shown that miR-33a
knockout mice develop obesity with increased prolifer-
ation of pre-adipocytes, increased lipid uptake, and im-
paired lipolysis [287, 288]; however, the effect of obe-
sity per se on miR-33a expression and abundance is not
known. Administration of a miR-33a mimetic to prima-
ry duck myoblasts impaired proliferation, while a miR-
33a inhibitor enhanced proliferation, and it was demon-
strated that miR-33a may directly target IGF-1,
follistatin, and cyclin-D1 to inhibit myoblast prolifera-
tion by suppressing the PI3K/Akt/mTOR signalling
pathway [289]. Taken together, these data suggest that
miR-33a is essential for normal adipocyte development
and function; however, its excessive abundance may
impair myogenesis. Thus, the declining levels of circu-
lating miR-33a seen with ageing may act to offset the
otherwise declining myogenic capacity of skeletal mus-
cle. However, more research is needed to unravel the
role of miR-33a in regulatingmuscle mass in the context
of ageing and obesity.
MyomiRs
Numerous muscle-enriched miRNAs (myomiRs) have
been implicated in myogenesis through their involve-
ment with myogenic regulatory factors [290–293].
GeroScience
Using microarrays, miR-133a and miR-133b, which
promote myoblast proliferation through repression of
SRF [86], were found to be downregulated in muscle
from healthy older men [89]. Conversely, elevated
levels of pri-miRNA-1-1, pri-miRNA-1-2, pri-miRNA-
133a-1, and pri-miRNA-133a-2 were found in the mus-
cle from elderly men, relative to younger men [90].
However, these differences did not exist at the mature
miRNA level, suggesting differential processing of pri-
and pre-miRNAs with ageing, although dissimilar to
prior findings, Drosha and Dicer protein or mRNA
expression were not different between young and older
men [90, 294].
Combined injection of miR-1, miR-133, and miR-
206 accelerates muscle regeneration in vivo, induces
myogenic expression, and promotes myoblast differen-
tiation in vitro [87, 293]. miR-1 promotes myogenesis
through targeting of the muscle gene transcriptional
repressor histone deacetylase 4 (HDAC4), and its ex-
pression and circulating abundance are suppressed by
HFD in mice [295, 296]; however, skeletal muscle
miR-1 mRNA expression was elevated in a murine
model of progeroid ageing [88]. miR-206 promotes
myoblast differentiation and directly represses
follistatin-like-1 and utrophin; however, its mRNA
expression was also found to be elevated in aged
mouse muscle [56, 91]. Pertinently, miR-206 ex-
pression in plasma was found to be downregulated
0.5-fold in children with overweight/obesity relative
to normal-weight children, suggesting a potential
mechanism by which obesity might adversely affect
myogenesis independent of ageing [297]. Similarly,
obesity is associated with downregulation of miR-
133a-3p in human SAT [298] and in mice HFD-
induced obesity downregulates miR-133b in WAT
[299]. Conversely, HFD-induced obesity upregulates
miR-133a in mouse muscle [295]; however, the
functional significance of these observations in the
context of regulating skeletal muscle mass remains
unclear.
It is growing ever more apparent that miRNAs play
vital roles in myogenesis and preliminary studies have
identified both interacting and diverging effects of obe-
sity and ageing on their expression and function. The
lack of consensus between these studies highlights the
need for further research, with an emphasis on transla-
tional studies to confirm findings from sequencing and
microarray studies, to delineate the impact of ageing and
obesity per se on the miRNA-mediated regulation of
skeletal muscle mass. The subsequent identification and
confirmation of differentially regulated adipose-muscle
cross talking miRNAs will doubtless present novel po-
tential therapeutic targets for muscle wasting conditions.
Conclusions and future directions
The regulation of skeletal muscle mass with ageing is
complex and delicately balanced, involving many se-
creted molecules (including proteins and RNAs), which
often display pleiotropic effects. Many of these factors
appear perturbed by excessive adiposity, but effects are
confounded by age, physical activity status, and comor-
bidities, frequently resulting in conflicting findings and
limited reproducibility. Indeed, the potent beneficial
effects of exercise on muscle-remodelling are a stark
contrast to the rapid deterioration of muscle mass and
function observed during periods of physical inactivity
and immobilisation, which feature in the lives of some,
but not all, elders. It is imperative therefore that every
effort is taken to control for physical activity status when
conducting human studies. Advances in proteomics and
transcriptomics are enabling greater investigation of the
secretomes of human muscle and adipose tissue in
healthy, dysfunctional, and senescent states. There is a
need, however, to extend the application of these tech-
niques beyond the cross-sectional studies that have
identified the differences in these secretomes, and to
apply them to longitudinal studies of human ageing.
Similarly, co-culture techniques using human primary
cells from well-characterised donors are improving
our understanding of these factors across the spec-
trums of health and ageing and offer greater relevance
to the human condition. Finally, advances in tech-
niques to investigate extracellular vesicles, to identify
novel non-coding RNAs, and to establish their func-
tional significance in regulating skeletal muscle mass
may identify novel therapeutic targets for preserving
muscle mass with ageing and increasing adiposity and
may enhance our understanding of the sarcopenic-
obese phenomenon.
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